Get started
Author

Diane Golebiowski

Observed names: D. Golebiowski, Golebiowski, Diane
ORCID: 0000-0002-5550-7883
Observed ORCID: 0000-0002-5550-7883
OpenAlex ID: A5035158067
The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma
2011 · Shwetal Mehta, Emmanuelle Huillard, et al. · Cancer Cell · 168
PDF
Requirement of the ATM/p53 Tumor Suppressor Pathway for Glucose Homeostasis
2010 · Heather L. Armata, Diane Golebiowski, et al. · Molecular and Cellular Biology · 123
Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation
2018 · Maria L. Allende, Emily K. Cook, et al. · Journal of Lipid Research · 109
PDF
Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain
2017 · Diane Golebiowski, Imramsjah M.J. van der Bom, et al. · Human Gene Therapy · 86
Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy
2023 · Sharla M. Birch, Michael W. Lawlor, et al. · Science Translational Medicine · 68
PDF
Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice
2018 · Tahnee L. Kennedy, Simon Guiraud, et al. · Molecular Therapy — Methods & Clinical Development · 44
PDF
Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice
2020 · Hannah G. Lahey, Chelsea J. Webber, et al. · Molecular Therapy · 37
PDF
A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy
2020 · Tatianna Wai Ying Wong, Abdalla Ahmed, et al. · Disease Models & Mechanisms · 34
A novel dual-plasmid platform provides scalable transfection yielding improved productivity and packaging across multiple AAV serotypes and genomes
2023 · Laura P. van Lieshout, Miranda Rubin, et al. · Molecular Therapy — Methods & Clinical Development · 29
PDF
Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing
2021 · Nagarathinam Selvaraj, Chao-Kuei Wang, et al. · Human Gene Therapy · 29
SGT-001 Micro-dystrophin gene therapy for Duchenne muscular dystrophy
2017 · J. Schneider, J. Gonzalez, et al. · Neuromuscular Disorders · 23
Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
2018 · Maire F. Osborn, Andrew H. Coles, et al. · Molecular Cancer Therapeutics · 20
An Improved Helper Plasmid Containing Deletions Within the E4 and E2a Genes Results in Increased Adeno-Associated Virus Productivity
2024 · Laura van Lieshout, Stacy Ota, et al. · Human Gene Therapy · 12
Anti-SOD1 Nanobodies That Stabilize Misfolded SOD1 Proteins Also Promote Neurite Outgrowth in Mutant SOD1 Human Neurons
2022 · Meenakshi Sundaram Kumar, Megan E. Fowler-Magaw, et al. · International Journal of Molecular Sciences · 8
PDF
AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System Involvement
2015 · Diane Golebiowski, Allison M. Bradbury, et al. · Neuromethods · 6
Structural analysis of recombinant AAV vector genomes at single-molecule resolution
2026 · David Rouleau, Dimpal Lata, et al. · PLoS ONE · 1
PDF
Quantification of microdystrophin and correlation to circulating biomarkers
2017 · K. Brown, M. Lawlor, et al. · Neuromuscular Disorders · 1
An engineered helper plasmid generates differential E4orf6 and L4-22/33K gene expression increasing AAV vector production
2026 · Laura van Lieshout, Katrina Costa-Grant, et al. · Gene Therapy
PDF
rAAV_Genome_Structural_Breakpoint_Analyzer
2026 · Rouleau, David, Lata, Dimpal, et al. · Zenodo (CERN European Organization for Nuclear Research)
rAAV_Structural_Variant_Classifier
2026 · Rouleau, David, Lata, Dimpal, et al. · Zenodo (CERN European Organization for Nuclear Research)
Correction: A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy
2025 · Tatianna Wai, Ying Wong, et al. · Disease Models & Mechanisms
PDF
Figure S1, Table S1, Table S2, Supplementary Methods from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
2023 · Maire F. Osborn, Andrew H. Coles, et al.
Data from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
2023 · Maire F. Osborn, Andrew H. Coles, et al.
Figure S1, Table S1, Table S2, Supplementary Methods from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
2023 · Maire F. Osborn, Andrew H. Coles, et al.
Data from Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs
2023 · Maire F. Osborn, Andrew H. Coles, et al.
Works count: 29
Citation count: 798
H-index: 12
I10-index: 13
Year
Topic
Type